Maravai LifeSciences (MRVI) director receives 46,293-share RSU award

Rhea-AI Filing Summary

ECKERT R ANDREW reported acquisition or exercise transactions in this Form 4 filing.

MARAVAI LIFESCIENCES HOLDINGS, INC. director R. Andrew Eckert received an equity award of 46,293 shares of Class A common stock in the form of restricted stock units. The award was granted at no cash cost to him and represents compensation rather than an open-market purchase.

These restricted stock units were granted under the company’s 2020 Omnibus Incentive Plan and will vest in full on the earlier of one year from the May 26, 2026 grant date or the date of the company’s 2027 annual meeting of stockholders. Following this award, Eckert directly holds 412,183 shares of Class A common stock.

Insider Trade Summary

Net Buyer: 46,293 shares

Net Buy 1 txn

Insider ECKERT R ANDREW

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Class A Common Stock	46,293	$0.00	$0.00

Holdings After Transaction: Class A Common Stock — 412,183 shares (Direct)

Footnotes (1)

1. F1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Key Figures

RSU grant size: 46,293 shares Grant price: $0.00 per share Post-transaction holdings: 412,183 shares +2 more

5 metrics

RSU grant size 46,293 shares Restricted stock units of Class A common stock granted May 26, 2026

Grant price $0.00 per share Equity compensation award, not an open-market purchase

Post-transaction holdings 412,183 shares Director’s direct Class A common stock holdings after the award

Vesting period Earlier of 1 year or 2027 meeting RSUs vest upon the earlier of one year from grant or 2027 annual meeting

Transaction direction Acquisition via grant Form 4 coded as grant, award, or other acquisition (Code A)

Key Terms

restricted stock units, 2020 Omnibus Incentive Plan, annual meeting of stockholders, Class A Common Stock

4 terms

restricted stock units financial

"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2020 Omnibus Incentive Plan financial

"awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026"

annual meeting of stockholders financial

"vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders"

Class A Common Stock financial

"security_title: "Class A Common Stock""

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 05/28/2026 - 06:26 PM Learn about SEC filing dates

FAQ

What insider transaction did MARAVAI LIFESCIENCES (MRVI) report for R. Andrew Eckert?

MARAVAI LIFESCIENCES reported that director R. Andrew Eckert received 46,293 restricted stock units of Class A common stock as a compensation award. The grant was made at no cash cost to him and increases his direct holdings to 412,183 shares after the transaction.

How many MARAVAI LIFESCIENCES (MRVI) shares does R. Andrew Eckert hold after this Form 4?

After the reported award, R. Andrew Eckert directly holds 412,183 shares of MARAVAI LIFESCIENCES Class A common stock. This total includes the newly granted 46,293 restricted stock units, which are structured as equity compensation under the company’s 2020 Omnibus Incentive Plan.

Was the MARAVAI LIFESCIENCES (MRVI) Form 4 transaction a market purchase or sale?

The Form 4 transaction was not a market purchase or sale. It reflects a grant of 46,293 restricted stock units at a price of $0.00 per share as a compensation award, rather than an open-market trade initiated by the director.

Under which plan were the MARAVAI LIFESCIENCES (MRVI) restricted stock units granted to R. Andrew Eckert?

The restricted stock units were granted under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan. This plan allows the company to issue equity-based awards such as restricted stock units to directors and other eligible participants as part of their compensation.

When do the MARAVAI LIFESCIENCES (MRVI) restricted stock units granted to R. Andrew Eckert vest?

The restricted stock units vest in full on the earlier of one year from the May 26, 2026 grant date or the date of the 2027 Maravai LifeSciences annual meeting of stockholders. This single-vest schedule ties vesting to time and the company’s shareholder meeting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

ECKERT R ANDREW

(Last) (First) (Middle)

C/O MARAVAI LIFESCIENCES HOLDINGS, INC.

10770 WATERIDGE CIR., SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	05/26/2026		A		46,293(1)	A	$0	412,183	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

Remarks:

	/s/ by Kurt Oreshack, by power of attorney for R. Andrew Eckert	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)